Stock comparison
IDEXX Laboratories
Ligand Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
LGND
Ligand Pharmaceuticals
Market cap
$4.6B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | LGND | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 55D | IDXX |
| Benjamin Graham | 80A | 67D | IDXX |
| Philip Fisher | 75B | 64C | IDXX |
| Peter Lynch | 71B | 54C | IDXX |
| Joel Greenblatt | 83C | 53D | IDXX |
| Charlie Munger | 87A | 57D | IDXX |
| Terry Smith | 84A | 47D | IDXX |
Side-by-side metrics
| Metric | IDXX | LGND |
|---|---|---|
| Market cap | $44.12B | $4.6B |
| P/E (TTM) | 39.0x | 27.6x |
| EV/EBIT | 31.6x | 97.7x |
| ROIC (TTM) | 40.66% | 5.61% |
| Gross margin | 62.05% | 98.61% |
| Net margin | 24.63% | 55.95% |
| Revenue CAGR 5y | 7.56% | 2.64% |
| EPS CAGR 5y | 10.79% | 16.8% |
| Debt / Equity | 0.7x | 0.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.12Bvs $4.6B+90%
- ROIC (TTM)40.66%vs 5.61%+86%
- EV/EBIT31.6xvs 97.7x+68%
- Revenue CAGR 5y7.56%vs 2.64%+65%
LGND leads on
- Net margin55.95%vs 24.63%+56%
- Gross margin98.61%vs 62.05%+37%
- EPS CAGR 5y16.8%vs 10.79%+36%
- Debt / Equity0.5xvs 0.7x+35%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.